Gilead's HCV Data Eclipse Fourth-Quarter Earnings Miss
Gilead Sciences Inc.'s fourth-quarter earnings fell short of expectations, but the Foster City, Calif.-based firm's stock jumped Friday on promising early data from newly acquired hepatitis C virus (HCV) drug GS-7977.
Suite: 1100 | Atlanta, Georgia 30346, USA
Outside of the US
In the U.S. and Canada: +1-877-857-2477
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
Sign up for Highlights FREE e-mail newsletter